M. Nasoff

发表

Immunochemical termination of self-tolerance

R. Lerner, P. Schultz, W. Ruf, 2008, Proceedings of the National Academy of Sciences.

Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.

Q. Deveraux, J. Efe, B. Eckelman, 2015, Veterinary immunology and immunopathology.

Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.

Q. Deveraux, P. Aza-Blanc, K. Wagner, 2004, Molecular biology of the cell.

LBY135, a novel anti‐DR5 agonistic antibody induces tumor cell–specific cytotoxic activity in human colon tumor cell lines and xenografts

Q. Deveraux, Youzhen Wang, C. Kowal, 2008 .

Molecular cloning, correlation of genetic and restriction maps, and determination of the direction of transcription of gnd of Escherichia coli

R. E. Wolf, M. Nasoff, 1980, Journal of bacteriology.

Identification of the immunoreactive peptide sequence for AgSK1, an adenocarcinoma-restricted antigen.

N. Saitō, M. Nasoff, M. Glassy, 2000, Tissue antigens.

Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells.

M. Nasoff, M. Glassy, S. Mukerjee, 1998, Hybridoma.

Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

T. Ganz, E. Nemeth, M. Nasoff, 2015, Blood.

Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids

G. S. Hunt, R. Lerner, P. Schultz, 2009, Proceedings of the National Academy of Sciences.

Identification of an immunodominant epitope within the capsid protein of hepatitis C virus.

S. Zebedee, G. Inchauspé, A. Prince, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Generation of a monoclonal antibody agonist to toll-like receptor 4.

M. Nasoff, S. Cohen, C. Gaskins, 2005, Hybridoma.

High-throughput expression of fusion proteins.

J. Heyman, J. Hoeffler, M. Nasoff, 2000, Methods in enzymology.

Patterns and prevalence of hepatitis C virus infection in posttransfusion non-A, non-B hepatitis.

A. Prince, M. Nasoff, B. Brotman, 1993, The Journal of infectious diseases.

Altered Cro repressors from engin of a synthetic cro gene (DNA synthesis/synthetic gene/protein-DNA interactions)

L. Bracco, D. Dodds, A. Stewart, 2016 .

Isolation and characterization of a cDNA clone for bovine cytochrome c oxidase subunit IV.

M. I. Lomax, M. Caruthers, L. Grossman, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Use of conserved sequences from hepatitis C virus for the detection of viral RNA in infected sera by polymerase chain reaction

S. Zebedee, A. Prince, M. Nasoff, 1991, Hepatology.

High-throughput proteomics

Scott A. Lesley, Marc Nasoff, Andreas Kreusch, 2001, SPIE BiOS.

A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.

Q. Deveraux, Yan Wang, M. Nasoff, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.

Marc Nasoff, I. H. Engels, Q. Deveraux, 2004, Cancer cell.

Activation and Suppression of the TRAIL Death-Receptor Pathway in Chemotherapy Sensitive and Resistant Follicular Lymphoma Cells

G. Hampton, Q. Deveraux, K. Wagner, 2003, Cancer biology & therapy.

Antitumor efficacy of LBY135, an anti-DR5 monoclonal antibody, alone or in combination with chemotherapy in human colon tumor cell lines and xenografts

Q. Deveraux, Youzhen Wang, D. Stover, 2007 .

Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates.

S. Zebedee, A. Prince, M. Nasoff, 1991, Proceedings of the National Academy of Sciences of the United States of America.

DNA sequence of the Escherichia coli gene, gnd, for 6-phosphogluconate dehydrogenase.

H. Baker, R. E. Wolf, M. Nasoff, 1984, Gene.

Cloning and expression of the human tumor-specific antibody GM4.

M. Nasoff, M. Glassy, S. Mukerjee, 1997, Hybridoma.

Isotype-directed enrichment of B cells by magnetic beads in the generation of immunoreactive human monoclonal antibodies.

M. Nasoff, M. Glassy, S. Mukerjee, 1996, Hybridoma.

IL-2 Immunotherapy Reveals Potential for Innate Beta Cell Regeneration in the Non-Obese Diabetic Mouse Model of Autoimmune Diabetes

P. McNamara, A. Herman, M. Londei, 2013, PloS one.

Altered Cro repressors from engineered mutagenesis of a synthetic cro gene.

M. Caruthers, L. Bracco, D. Dodds, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).

E. Small, E. Heath, Jiaoti Huang, 2022, Journal of Clinical Oncology.

Binding studies of SV40 T-antigen to SV40 binding site II.

M. Caruthers, P. Gottlieb, M. Nasoff, 1985, Nucleic acids research.